WO2022255836A1 - 조직 내재성 uPAR+/Nestin+ 줄기세포 분리 배양 방법 및 이의 용도 - Google Patents
조직 내재성 uPAR+/Nestin+ 줄기세포 분리 배양 방법 및 이의 용도 Download PDFInfo
- Publication number
- WO2022255836A1 WO2022255836A1 PCT/KR2022/007910 KR2022007910W WO2022255836A1 WO 2022255836 A1 WO2022255836 A1 WO 2022255836A1 KR 2022007910 W KR2022007910 W KR 2022007910W WO 2022255836 A1 WO2022255836 A1 WO 2022255836A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tissue
- upar
- cells
- hydrogel
- stem cells
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 148
- 238000000034 method Methods 0.000 title claims abstract description 113
- 102000008730 Nestin Human genes 0.000 title claims abstract description 94
- 108010088225 Nestin Proteins 0.000 title claims abstract description 94
- 210000005055 nestin Anatomy 0.000 title claims abstract description 93
- 238000012258 culturing Methods 0.000 title claims abstract description 23
- 210000004027 cell Anatomy 0.000 claims abstract description 382
- 210000001519 tissue Anatomy 0.000 claims abstract description 227
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 claims abstract description 180
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 claims abstract description 180
- 230000000694 effects Effects 0.000 claims abstract description 63
- 229940012957 plasmin Drugs 0.000 claims abstract description 56
- 230000010261 cell growth Effects 0.000 claims abstract description 31
- 230000032823 cell division Effects 0.000 claims abstract description 26
- 230000004069 differentiation Effects 0.000 claims abstract description 17
- 230000012292 cell migration Effects 0.000 claims abstract description 14
- 239000000017 hydrogel Substances 0.000 claims description 246
- 239000002797 plasminogen activator inhibitor Substances 0.000 claims description 152
- 102000010752 Plasminogen Inactivators Human genes 0.000 claims description 150
- 108010077971 Plasminogen Inactivators Proteins 0.000 claims description 150
- 239000001963 growth medium Substances 0.000 claims description 100
- 230000014509 gene expression Effects 0.000 claims description 92
- 230000037314 wound repair Effects 0.000 claims description 87
- 239000011159 matrix material Substances 0.000 claims description 84
- 210000002027 skeletal muscle Anatomy 0.000 claims description 74
- 210000001185 bone marrow Anatomy 0.000 claims description 66
- 108010073385 Fibrin Proteins 0.000 claims description 61
- 102000009123 Fibrin Human genes 0.000 claims description 61
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 61
- 229950003499 fibrin Drugs 0.000 claims description 61
- 238000011282 treatment Methods 0.000 claims description 58
- 230000012010 growth Effects 0.000 claims description 47
- 238000005406 washing Methods 0.000 claims description 47
- 210000000578 peripheral nerve Anatomy 0.000 claims description 44
- 210000000577 adipose tissue Anatomy 0.000 claims description 43
- 229920001436 collagen Polymers 0.000 claims description 39
- 108010035532 Collagen Proteins 0.000 claims description 38
- 102000008186 Collagen Human genes 0.000 claims description 38
- 108010088842 Fibrinolysin Proteins 0.000 claims description 37
- 238000000338 in vitro Methods 0.000 claims description 28
- 239000008273 gelatin Substances 0.000 claims description 24
- 229920000159 gelatin Polymers 0.000 claims description 24
- 108010010803 Gelatin Proteins 0.000 claims description 22
- 235000019322 gelatine Nutrition 0.000 claims description 22
- 235000011852 gelatine desserts Nutrition 0.000 claims description 22
- 210000005222 synovial tissue Anatomy 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 239000004480 active ingredient Substances 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 18
- 230000001939 inductive effect Effects 0.000 claims description 15
- 230000017423 tissue regeneration Effects 0.000 claims description 14
- 108010049003 Fibrinogen Proteins 0.000 claims description 12
- 102000008946 Fibrinogen Human genes 0.000 claims description 12
- 229940012952 fibrinogen Drugs 0.000 claims description 12
- 230000002107 myocardial effect Effects 0.000 claims description 12
- 108090000190 Thrombin Proteins 0.000 claims description 10
- 229960004072 thrombin Drugs 0.000 claims description 10
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 10
- 229960000401 tranexamic acid Drugs 0.000 claims description 10
- 230000004913 activation Effects 0.000 claims description 9
- 229960003375 aminomethylbenzoic acid Drugs 0.000 claims description 8
- QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 claims description 8
- 230000003213 activating effect Effects 0.000 claims description 7
- 230000008929 regeneration Effects 0.000 claims description 7
- 238000011069 regeneration method Methods 0.000 claims description 7
- 238000002955 isolation Methods 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 210000004204 blood vessel Anatomy 0.000 claims description 5
- 238000012136 culture method Methods 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 206010052428 Wound Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 230000000593 degrading effect Effects 0.000 claims description 3
- 230000008054 signal transmission Effects 0.000 claims description 2
- 238000013508 migration Methods 0.000 abstract description 35
- 230000005012 migration Effects 0.000 abstract description 27
- 230000028327 secretion Effects 0.000 abstract description 12
- 239000007787 solid Substances 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 5
- 229940124597 therapeutic agent Drugs 0.000 abstract description 4
- 229960000074 biopharmaceutical Drugs 0.000 abstract description 3
- 230000024245 cell differentiation Effects 0.000 abstract description 2
- 238000009509 drug development Methods 0.000 abstract description 2
- 210000001808 exosome Anatomy 0.000 abstract description 2
- 230000001766 physiological effect Effects 0.000 abstract description 2
- 210000000056 organ Anatomy 0.000 description 95
- 210000004165 myocardium Anatomy 0.000 description 74
- 229960005356 urokinase Drugs 0.000 description 66
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 64
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 64
- 239000000243 solution Substances 0.000 description 47
- 210000001258 synovial membrane Anatomy 0.000 description 40
- 210000005036 nerve Anatomy 0.000 description 31
- 230000007774 longterm Effects 0.000 description 25
- 230000015556 catabolic process Effects 0.000 description 20
- 238000006731 degradation reaction Methods 0.000 description 20
- 239000003636 conditioned culture medium Substances 0.000 description 18
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 16
- 102000006495 integrins Human genes 0.000 description 15
- 108010044426 integrins Proteins 0.000 description 15
- 238000003756 stirring Methods 0.000 description 14
- 238000010899 nucleation Methods 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 210000003556 vascular endothelial cell Anatomy 0.000 description 12
- 210000001789 adipocyte Anatomy 0.000 description 11
- 210000000963 osteoblast Anatomy 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 230000019491 signal transduction Effects 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 239000002356 single layer Substances 0.000 description 10
- 210000000805 cytoplasm Anatomy 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 8
- 230000003278 mimic effect Effects 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 7
- 102000035195 Peptidases Human genes 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 230000001120 cytoprotective effect Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000012188 paraffin wax Substances 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 230000005754 cellular signaling Effects 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 230000008354 tissue degradation Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 230000001172 regenerating effect Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 230000005779 cell damage Effects 0.000 description 4
- 208000037887 cell injury Diseases 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000004264 monolayer culture Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000000451 tissue damage Effects 0.000 description 4
- 231100000827 tissue damage Toxicity 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 3
- 102000004121 Annexin A5 Human genes 0.000 description 3
- 102100037241 Endoglin Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 102100025304 Integrin beta-1 Human genes 0.000 description 3
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000000984 immunochemical effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000003668 pericyte Anatomy 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 102100022464 5'-nucleotidase Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000007204 Brain death Diseases 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 239000006147 Glasgow's Minimal Essential Medium Substances 0.000 description 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102100039419 Plasminogen activator inhibitor 2 Human genes 0.000 description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 2
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012533 medium component Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000030968 tissue homeostasis Effects 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 108010065822 urokinase inhibitor Proteins 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010000196 Factor XIIIa Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 102100038126 Tenascin Human genes 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N beta-glycerol phosphate Natural products OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
- GHRQXJHBXKYCLZ-UHFFFAOYSA-L beta-glycerolphosphate Chemical compound [Na+].[Na+].CC(CO)OOP([O-])([O-])=O GHRQXJHBXKYCLZ-UHFFFAOYSA-L 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 108010015046 cell aggregation factors Proteins 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000004261 periodontium Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010807 real-time PCR kit Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 101150077014 sox10 gene Proteins 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/56—Fibrin; Thrombin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0653—Adipocytes; Adipose tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
Definitions
- the present invention relates to a method for isolating and culturing uPAR+/Nestin+ tissue endogenous stem cells, which play a key role in tissue regeneration and tissue homeostasis in solid tissues, and uses thereof.
- a conventional method for isolating and culturing stem cells present in solid tissue is a single cell suspension ( A process for manufacturing a single cell suspension) is required.
- the yield of single cells obtained varies greatly depending on the type of tissue degradation enzyme used, the titer, the reaction time, the reaction temperature, and the type of tissue used.
- cell damage during the tissue dissociation process has been raised as an unavoidable problem.
- the tissue dissociation process showed a large difference in cell yield and degree of damage depending on the tissue type, and presented a disadvantage that it was difficult to standardize.
- the frequency of stem cells in solid tissue is less than 0.1%, and it is widely known that the yield of isolating an effective amount of stem cells through tissue degradation enzymes is extremely low.
- a subsequent process of separating and purifying the tissue endogenous stem cells from the single cell suspension dissociated from the tissue is required.
- the process of separating and purifying stem cells uses markers such as c-Kit or Sca-1 to separate cells positive or negative for the marker.
- markers are markers that are expressed not only in tissue-intrinsic stem cells but also in hematopoietic cells, so unwanted cells can be mixed and separated.
- stem cells negative for these markers definitely exist, tissue-intrinsic stem cells using specific markers Methods for isolating and purifying cells have limitations.
- An object of the present invention is to activate tissue endogenous uPAR+/nestin+ stem cells located in solid tissues such as adipose tissue, bone marrow tissue, myocardial tissue, peripheral nerve tissue, skeletal muscle tissue or synovial tissue, induce migratory growth, and isolate to provide a way to do it.
- Another object of the present invention is to provide tissue endogenous uPAR+ and nestin+ stem cells or a culture solution thereof separated and cultured according to the above method.
- another object of the present invention is to provide a pharmaceutical composition for preventing or treating inflammatory diseases or autoimmune diseases, comprising the tissue-intrinsic uPAR+ and nestin+ stem cells or their culture medium as an active ingredient.
- Another object of the present invention is to provide a pharmaceutical composition for wound healing or vascular regeneration promotion, comprising the tissue-intrinsic uPAR+ and nestin+ stem cells or their culture medium as an active ingredient.
- the present invention comprises the steps of (1) preparing a wound repair matrix mimic hydrogel; (2) incorporating the separated tissue sections into the wound repair matrix mimicking hydrogel; and (3) three-dimensionally culturing the wound repair matrix-mimicking hydrogel incorporating the tissue fragment in a culture medium to which a plasminogen activator inhibitor (PAI) is added. provides an activation method.
- PAI plasminogen activator inhibitor
- the present invention comprises the steps of (1) preparing a wound repair matrix mimic hydrogel; (2) incorporating the separated tissue sections into the wound repair matrix mimicking hydrogel; (3) three-dimensionally culturing the wound repair matrix mimicking hydrogel incorporating the tissue slice in a culture medium to which PAI is added; (4) removing and washing the three-dimensional culture medium to remove PAI; (5) degrading the wound repair matrix mimicking hydrogel by re-cultivating the PAI-free culture medium with a PAI-free culture medium; and (6) isolating stem cells released from the culture medium.
- the present invention provides tissue endogenous uPAR+ and nestin+ stem cells or a culture solution thereof, separated and cultured according to the above method.
- the present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases comprising the tissue-specific uPAR+ and nestin+ stem cells or their culture medium as an active ingredient.
- the present invention provides a pharmaceutical composition for the prevention or treatment of autoimmune diseases comprising the tissue-specific uPAR+ and nestin+ stem cells or their culture medium as an active ingredient.
- the present invention provides a pharmaceutical composition for wound treatment comprising the tissue-endogenous uPAR+ and nestin+ stem cells or their culture medium as an active ingredient.
- the present invention provides a pharmaceutical composition for promoting blood vessel regeneration comprising the tissue-endogenous uPAR+ and nestin+ stem cells or their culture medium as an active ingredient.
- the present invention relates to a method for separating and culturing tissue-intrinsic uPAR+/Nestin+ stem cells and a use thereof, and provides a method for isolating tissue-intrinsic stem cells present in solid tissues based on uPAR-plasmin activity.
- the uPAR-plasmin activity of stem cells is closely related to the growth, migration ability, physiological activity, and differentiation ability of stem cells, and can be used as a method for isolating high-titer stem cells.
- the uPAR+ stem cells isolated from the solid tissue of the present invention have great industrial potential as they can be applied to the production of biopharmaceuticals using secretions including cell therapy agents, tissue engineering therapeutic agents, and exosomes.
- it can be applied to cell biology, molecular biology basic research and new drug development research related to cell division, migration, growth, and differentiation of tissue endogenous stem cells.
- Figure 1 shows the expression rates of pFAK, uPAR, nestin, and Ki-67 in constituent cells in organs after in vitro organ culture.
- 2D monolayer organ culture
- 3D 3D organ culture
- AT adipose tissue
- BM bone marrow
- Myocar myocardium
- PN peripheral nerve
- SM skeletal muscle
- Syn Synovium. **, p ⁇ 0.01 versus 2D.
- Figure 2 shows the characteristics of increasing pFAK+, uPAR+, and Nestin+ expressing cells in the myocardium according to 3D myocardial organ culture.
- Figure 3 shows the characteristics of increasing ki-67 positive cells during cell division in the myocardium according to 3D organ culture.
- Fig. 5 shows uPAR, nestin and BrdU expression of cells grown in hydrogel after 3D myocardial organ culture.
- Figure 6 shows the uPAR and nestin expression rates of cells grown by migration into hydrogels after 2 weeks of 3D organ culture.
- AT adipose tissue
- BM bone marrow
- Myocar myocardium
- PN peripheral nerve
- SM skeletal muscle
- Syn Synovium.
- FIG. 7 shows uPAR mRNA (A) and plasmin activity (B) in organs before and after 3 days of organ culture.
- AT adipose tissue
- BM bone marrow
- Myocar myocardium
- PN peripheral nerve
- SM skeletal muscle
- Syn Synovium. *, p ⁇ 0.05 versus pre-culture; **, p ⁇ 0.01 versus pre-culture.
- Figure 8 shows that the hydrogel is degraded through the removal of PAI in the culture medium and washing of the culture medium after long-term culture, and the cells that have migrated and grown in the hydrogel are released into the culture medium.
- Figure 9 shows that the cells that have migrated and grown in the hydrogel are separated from the hydrogel through the removal of PAI in the culture medium and washing of the culture medium, and the free cells are contracted and aggregated (phase contrast micrograph).
- Figure 10 shows the isolation of free uPAR+ cells in the hydrogel after PAI removal and washing of the culture (paraffin section HE staining and uPAR immunohistochemical staining).
- Figure 11 shows the cell yield and uPAR expression rate of the cells separated and harvested after PAI removal and culture washing (PAI withdrawn) and separation from the hydrogel after the addition of exogenous Urokinase.
- AT adipose tissue
- BM bone marrow
- Myocar myocardium
- PN peripheral nerve
- SM skeletal muscle
- Syn Synovium. **, p ⁇ 0.01 versus urokinase.
- FIG. 12 shows the cell yield obtained after repeatedly separating the tissue slices recovered from the hydrogel through repetitive long-term culture after removing PAI and washing the culture.
- AT adipose tissue
- BM bone marrow
- Myocar myocardium
- PN peripheral nerve
- SM skeletal muscle
- Syn Synovium.
- Figure 13 shows the cell attachment and growth in a monolayer culture environment after seeding the cells harvested after PAI removal and culture washing in a culture container.
- A Cell aggregates released from the hydrogel after PAI removal and washing.
- B Cell aggregates harvested from the hydrogel.
- C-E Attachment and growth of cells at 30 minutes (C), 1 hour (D), and 2 hours (D) after seeding the recovered cells in the culture container (phase contrast micrographs).
- Figure 15 shows adhesion and growth in a monolayer culture environment of cells released from the hydrogel after removal of PAI and washing of the culture after nerve and myocardial organ culture.
- FIG. 16 shows immunorepresentation characteristics of cells recovered from hydrogels.
- A Immunoexpression characteristics of cells released after withdrawal from hydrogel after removal of PAI and washing of culture.
- B Immunoexpression characteristics of cells released from the hydrogel after exogenous Urokinase treatment.
- AT adipose tissue
- BM bone marrow
- Myocar myocardium
- PN peripheral nerve
- SM skeletal muscle
- Syn Synovium. **, p ⁇ 0.01 versus urokinase (B).
- FIG. 17 shows the expression rates of hematopoietic cell and vascular endothelial cell markers in cells recovered from the hydrogel.
- A Expression rate of cells isolated and recovered after removal of PAI and washing of the culture.
- B Expression rate of cells isolated and recovered after treatment with exogenous Urokinase.
- AT adipose tissue
- BM bone marrow
- Myocar myocardium
- PN peripheral nerve
- SM skeletal muscle
- Syn Synovium. **, p ⁇ 0.01 versus urokinase (B).
- FIG. 18 shows the self-renewal ability of cells separated and recovered from the hydrogel.
- A Representative photographs of Colony Forming Unit (CFU).
- B CFU frequency of cells separated and harvested from hydrogels according to tissue origin. Cells isolated and recovered after treatment with urokinase and exogenous urokinase; Cells isolated and recovered after PAI withdrawal, PAI removal, and culture washing; AT, adipose tissue; BM, bone marrow; Myocar, myocardium; PN, peripheral nerve; SM, skeletal muscle; Syn, Synovium. **, p ⁇ 0.01 versus urokinase.
- A Population Doubling Time (PDT, cell doubling time).
- B Population Doubling Level (PDL, cell doubling level).
- AT adipose tissue;
- BM bone marrow;
- Myocar myocardium;
- PN peripheral nerve;
- SM skeletal muscle; Syn, Synovium.
- * p ⁇ 0.05 versus urokinase; **, p ⁇ 0.01 versus urokinase.
- FIG. 20 shows the Ki-67 expression rate of cells separated and recovered from the hydrogel.
- FIG. 21 shows the differentiation ability of the cells separated and recovered from the hydrogel into osteoblasts (alizarin red) and adipocytes (Oil Red O).
- Ostin red alizarin red
- adipocytes Oleoblasts
- Cells isolated and recovered after treatment with urokinase and exogenous urokinase Cells isolated and recovered after PAI withdrawal, removal of PAI, and washing of the culture.
- FIG. 22 shows a comparison of the differentiation abilities of cells separated and recovered from the hydrogel into osteoblasts (alizarin red) and adipocytes (Oil Red O).
- Ostwald red adipocytes
- Cells isolated and recovered after PAI withdrawal, PAI removal, and culture washing AT, adipose tissue
- BM bone marrow
- Myocar myocardium
- PN peripheral nerve
- SM skeletal muscle
- Syn Synovium. **, p ⁇ 0.01 versus urokinase.
- Figure 23 shows the tissue regeneration mRNA expression characteristics of the cells separated and recovered from the hydrogel.
- CB-MSC cord blood-derived mesenchymal stem cells; AT, adipose tissue; BM, bone marrow; Myocar, myocardium; PN, peripheral nerve; SM, skeletal muscle; Syn, Synovium.
- uPAR- uPAR-negative cells isolated and purified after treatment with exogenous urokinase
- uPAR+, uPAR+ cells isolated and purified after treatment with exogenous urokinase
- Cells isolated and harvested after PAI withdrawal, PAI removal and washing of the culture AT, adipose tissue
- BM bone marrow
- Myocar myocardium
- PN peripheral nerve
- SM skeletal muscle
- Syn Synovium. *, p ⁇ 0.05 versus uPAR-; **, p, uPAR- versus 0.01. *, p ⁇ 0.05 versus uPAR-; **, p ⁇ 0.01 versus uPAR-.
- uPAR- uPAR-negative cells isolated and purified after treatment with exogenous urokinase
- uPAR+, uPAR+ cells isolated and purified after treatment with exogenous urokinase
- Cells isolated and harvested after PAI withdrawal, PAI removal and washing of the culture AT, adipose tissue
- BM bone marrow
- Myocar myocardium
- PN peripheral nerve
- SM skeletal muscle
- Syn Synovium. *, p ⁇ 0.05 versus uPAR-; **, p, uPAR- versus 0.01. *, p ⁇ 0.05 versus uPAR-; **, p ⁇ 0.01 versus uPAR-.
- FIG. 26 shows the anti-inflammatory ability of cells separated and recovered from the hydrogel. Inhibiting the secretion of TNF ⁇ and IL-1 ⁇ in RAW 264.7 cells sensitized with LPS in the conditioned medium.
- uPAR+, uPAR+ cells isolated and purified after treatment with exogenous urokinase;
- Cells isolated and harvested after PAI withdrawal, PAI removal and washing of the culture AT, adipose tissue; BM, bone marrow; Myocar, myocardium; PN, peripheral nerve; SM, skeletal muscle; Syn, Synovium.
- FIG. 27 shows the growth inducing effect of vascular endothelial cells (HUVEC) and fibroblasts (DF) of the cells separated and recovered from the hydrogel.
- uPAR+, uPAR+ cells isolated and purified after treatment with exogenous urokinase;
- uPAR- vascular endothelial cells
- DF fibroblasts
- 29 shows a schematic diagram of the present invention compared to the existing technology.
- the present invention comprises the steps of (1) preparing a hydrogel mimicking a wound repair matrix; (2) incorporating the separated tissue sections into the wound repair matrix mimicking hydrogel; and (3) three-dimensionally culturing the wound repair matrix-mimicking hydrogel incorporating the tissue fragment in a culture medium to which a plasminogen activator inhibitor (PAI) is added. provides an activation method.
- PAI plasminogen activator inhibitor
- the wound repair matrix mimicking hydrogel is a fibrin hydrogel in which a 0.25 to 2.5% concentration of a fibrinogen solution and a 0.5 to 5 I.U./mL concentration of a thrombin solution are mixed, and a 0.1 to 0.5% concentration of collagen in the fibrin hydrogel.
- It may be a fibrin/collagen mixed hydrogel in which the solution is mixed or a fibrin/gelatin mixed hydrogel in which a 0.1 to 0.5% gelatin solution is mixed with the fibrin hydrogel, but is not limited thereto.
- the tissue may be adipose tissue, bone marrow tissue, myocardial tissue, peripheral nerve tissue, skeletal muscle tissue or synovial tissue, but is not limited thereto.
- the PAI may be tranexamic acid or aminomethyl benzoic acid, but is not limited thereto.
- the method activates integrin-FAK cell signal transduction of cells in the tissue to induce cell division and cell growth of tissue endogenous uPAR+ and nestin+ stem cells, but is not limited thereto.
- the method may induce cell migration and cell growth of the tissue-intrinsic uPAR+ and nestin+ stem cells into the wound repair matrix-mimicking hydrogel, but is not limited thereto.
- a tissue-specific wound repair matrix is required. It can be prepared using biopolymers by mimicking wound repair matrix components formed by coagulation of blood plasma released from blood vessels after tissue damage.
- the wound repair matrix may be prepared by using fibrin, collagen, or gelatin alone or in combination.
- Engineered wound repair substrates have different uPA-plasmin activity depending on the organ, and wound repair substrates resistant to uPA-plasmin activity can be manufactured and used.
- the wound repair matrix can be prepared by adjusting the content or composition of biopolymers.
- a wound repair matrix mixed with two or more components such as fibrin-collagen, fibrin-gelatin, or collagen-gelatin may be used.
- the wound repair matrix of the present invention may be constituted in an amount of 1.0 to 20.0 mg/ml of constituent polymers such as fibrinogen, collagen, and gelatin.
- the degree of crosslinking can be adjusted to enhance the structural properties of the wound repair matrix, and structural properties can be controlled by adjusting the degree of crosslinking of the wound repair matrix using a crosslinking agent such as Ca++ or Factor XIIIa.
- Activation of cell signaling pathways is required to induce cell division and growth of stem cells in tissues through in vitro culture. It binds to the cell's integrin ligand and transmits and activates signals that can induce cell growth and migration through the wound repair matrix. It can induce cell division, growth and migration of stem cells in tissue as it supports tissue as a wound repair matrix that can directly bind to cell integrins and transmit signals into cells. Integrin- ⁇ 1-FAK signaling pathway transmits signals through integrin to tissue-intrinsic stem cells and induces activation according to the support of the wound repair matrix, and tissue-intrinsic stem cells increase expression of uPAR and nestin according to the transmitted signals and can induce the division, growth and migration of regenerative stem cells in tissues.
- the present invention can achieve the above object by preparing a wound repair matrix mimicking hydrogel composed of a polymer having an RGD motif such as fibrin, collagen, gelatin, etc. as a wound repair matrix capable of activating the integrin-FAK cell signaling pathway.
- the present invention provides a method for inducing cell division, growth and migration of tissue endogenous stem cells by activating the Integrin- ⁇ 1-FAK-uPAR signaling pathway.
- Signal transduction efficiency to stem cells in tissues is proportional to the density of receptors that can bind integrin ligand.
- Receptor density that can bind integrin ligand can be achieved by increasing the contact surface with the tissue.
- the area that can be bonded to cells can be increased, thereby increasing integrin ligand and receptor binding.
- the efficiency of signal transduction to stem cells in tissues can be increased.
- the present invention provides a method for activating the Integrin- ⁇ 1-FAK-uPAR signaling pathway by providing an artificial wound repair matrix as a three-dimensional support to tissue.
- a method of strengthening the signal transduction pathway by providing a three-dimensional bond to tissue slices using a hydrogel capable of sol-gel phase transition as a wound repair substrate.
- uPA-plasmin activity can vary depending on the tissue, degree of damage and cause. Compared to fat, placenta, and umbilical cord, nervous system tissue has higher uPA-plasmin activity, and as a result, the degree of degradation of wound repair matrix is higher in nervous system tissue.
- Decomposition of the wound repair matrix can be controlled by adjusting the content of components constituting the wound repair matrix, the molecular weight of the polymer, and the degree of crosslinking.
- the present invention provides a method for controlling the resistance to uPA-plasmin activity to be increased by increasing the content, molecular weight, and degree of crosslinking of the polymers constituting the wound repair matrix.
- PAI applicable to the present invention may be selected from the group consisting of aminocaproid acid, tranexamic acid, aprotinin, and aminomethylbenzoic acid.
- PAI applied to the present invention can be used by adding 10 ⁇ g to 10 mg per ml of hydrogel volume.
- the present invention provides a method for inducing and supporting the growth and migration of tissue endogenous stem cells during the long-term culture period by adding PAI and maintaining the structural stability of the wound repair matrix.
- the activity of uPAR-uPA-plasmin in excessive stem cells results in the rapid decomposition of the wound repair matrix-mimicking hydrogel during the in vitro culture process, resulting in the degradation and loss of tissue fragments and the wound repair matrix around the cells.
- stem cells can attach and migrate Loss of the repair substrate may result, resulting in loss or reduction or loss of cell migration from the tissue into the hydrogel.
- the present invention controls the excessive plasmin activity of stem cells and tissue slices by adding PAI to control the degradation and loss of excessive wound repair matrix mimicking hydrogel, so that the wound repair matrix mimicking hydrogel physically destroys the tissue slice during the long-term culture period.
- Provided is a method for maintaining a role as a support substrate and at the same time maintaining a structural and functional role as a substrate on which activated tissue endogenous stem cells can migrate and grow.
- the present invention comprises the steps of (1) preparing a wound repair matrix mimic hydrogel; (2) incorporating the separated tissue sections into the wound repair matrix mimicking hydrogel; (3) three-dimensionally culturing the wound repair matrix mimicking hydrogel incorporating the tissue slice in a culture medium to which PAI is added; (4) removing and washing the three-dimensional culture medium to remove PAI; (5) degrading the wound repair matrix mimicking hydrogel by re-cultivating the PAI-free culture medium with a PAI-free culture medium; and (6) isolating stem cells released from the culture medium.
- the wound repair matrix mimicking hydrogel is a fibrin hydrogel in which a 0.25 to 2.5% concentration of a fibrinogen solution and a 0.5 to 5 I.U./mL concentration of a thrombin solution are mixed, and a 0.1 to 0.5% concentration of collagen in the fibrin hydrogel.
- It may be a fibrin/collagen mixed hydrogel in which the solution is mixed or a fibrin/gelatin mixed hydrogel in which a 0.1 to 0.5% gelatin solution is mixed with the fibrin hydrogel, but is not limited thereto.
- the tissue may be adipose tissue, bone marrow tissue, myocardial tissue, peripheral nerve tissue, skeletal muscle tissue or synovial tissue, but is not limited thereto.
- the PAI may be tranexamic acid or aminomethyl benzoic acid, but is not limited thereto.
- the step (5) induces an increase in uPAR expression in the tissue and decomposes the wound repair matrix mimicking hydrogel through an increase in plasmin activity, but is not limited thereto.
- tissue-intrinsic uPAR+ and nestin+ stem cells may have enhanced self-renewal ability, in vitro growth ability, differentiation potential, or tissue regeneration inducing ability, but are not limited thereto.
- the tissue slices recovered from the culture medium in step (5) may further include repeating steps (2) to (5) 1 to 10 times, but is not limited thereto.
- the present invention provides a method for selectively isolating uPAR+ stem cells that have migrated and grown into the wound repair matrix.
- the degradation of the wound repair matrix due to excessive uPAR-plasmin activity can be controlled through the addition of PAI, a method for recovering cells from the wound repair matrix after the targeted migration and growth of stem cells is achieved is provided. As PAI is removed after washing, the wound repair matrix is degraded using the uPAR-plasmin activity characteristic inherent in stem cells, and the stem cells that have migrated and grown in the matrix are liberated and recovered.
- the present invention provides a method for isolating uPAR+ stem cells from solid tissue without the use of any exogenous protease and subsequent purification, wherein the wound repair matrix is degraded according to uPAR expression rate and plasmin activity in stem cells by uPAR-plasmin. .
- the present invention provides a method for recovering tissue slices used for organ culture in a state in which the structure and function are preserved by not using any exogenous tissue degradation enzymes. Tissue fragments recovered after long-term culture are preserved in their structure, and thus, a method of inducing migration of uPAR+ tissue endogenous stem cells into the wound repair matrix through repeated long-term culture is provided.
- the present invention provides a composition of a wound repair matrix that differs in uPAR-uPA-plasmin activity of tissue endogenous stem cells depending on the tissue and is not lost due to degradation by uPAR-uPA-plasmin activity according to the tissue, and controls excessive degradation.
- uPAR+/nestin+ tissue endogenous stem cells can be used to manufacture stem cell therapeutic agents and stem cell-derived biopharmaceuticals with high self-replication, in vitro growth, differentiation ability, tissue regeneration-inducing gene expression, blood vessel regeneration and wound repair effects.
- the present invention provides tissue endogenous uPAR+ and nestin+ stem cells or a culture solution thereof, separated and cultured according to the above method.
- culture medium includes a medium capable of supporting the growth and survival of stem cells in vitro, secretions of cultured stem cells contained in the medium, and the like.
- the medium used for the culture includes all conventional mediums used in the art suitable for culturing stem cells.
- Media and culture conditions can be selected according to the type of cell.
- the medium used for culture is preferably a cell culture minimum medium (CCMM), and generally contains a carbon source, a nitrogen source, and trace elements.
- Such cell culture minimal media include, for example, DMEM (Dulbecco's Modified Eagle's Medium), MEM (Minimal essential Medium), BME (Basal Medium Eagle), RPMI1640, F-10, F-12, ⁇ MEM ( ⁇ Minimal essential Medium), GMEM. (Glasgow's Minimal essential Medium), Iscove's Modified Dulbecco's Medium, etc., but are not limited thereto.
- the present invention is a form containing all of the stem cells, their secretions, and medium components, a form containing only secretions and medium components, a form in which only secretions are separated and used alone or together with stem cells, or by administering only stem cells It is also possible to use it in a form that produces secretions in the body.
- the stem cells may be obtained using any method commonly known in the art.
- the present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases comprising the tissue-specific uPAR+ and nestin+ stem cells or their culture medium as an active ingredient.
- the present invention provides a pharmaceutical composition for the prevention or treatment of autoimmune diseases comprising the tissue-specific uPAR+ and nestin+ stem cells or their culture medium as an active ingredient.
- the present invention provides a pharmaceutical composition for wound treatment comprising the tissue-endogenous uPAR+ and nestin+ stem cells or their culture medium as an active ingredient.
- the present invention provides a pharmaceutical composition for promoting blood vessel regeneration comprising the tissue-endogenous uPAR+ and nestin+ stem cells or their culture medium as an active ingredient.
- Tissue endogenous uPAR+ and nestin+ stem cells of the present invention can be used as a cell therapy agent for the treatment of specific diseases, and the treatment can be direct treatment or pre-treatment of the molecules.
- the "cell therapy product” means a product that changes the biological properties of cells by proliferating or selecting living autologous, allogenic, or xenogenic cells in vitro in order to restore the function of cells and tissues or by other methods.
- Drugs used for treatment, diagnosis, and prevention through a series of actions such as
- the cell therapy may be administered to the human body through any general route as long as it can reach the target tissue.
- the pharmaceutical composition of the present invention can be prepared using a pharmaceutically suitable and physiologically acceptable adjuvant in addition to the active ingredient, and the adjuvant includes an excipient, a disintegrant, a sweetener, a binder, a coating agent, an expanding agent, a lubricant, and a glidant. Alternatively, a solubilizer such as a flavoring agent may be used.
- the pharmaceutical composition of the present invention may be preferably formulated as a pharmaceutical composition by including one or more pharmaceutically acceptable carriers in addition to the active ingredient for administration.
- acceptable pharmaceutical carriers are sterile and biocompatible, and include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added if necessary.
- diluents, dispersants, surfactants, binders, and lubricants may be additionally added to prepare formulations for injections such as aqueous solutions, suspensions, and emulsions, pills, capsules, granules, or tablets.
- the pharmaceutical formulation form of the pharmaceutical composition of the present invention may be granules, powders, coated tablets, tablets, capsules, suppositories, syrups, juices, suspensions, emulsions, drops or injectable solutions, and sustained-release preparations of active compounds.
- the pharmaceutical composition of the present invention can be administered in a conventional manner through intravenous, intraarterial, intraperitoneal, intramuscular, intraarterial, intraperitoneal, intrasternal, transdermal, intranasal, inhalational, topical, rectal, oral, intraocular or intradermal routes.
- An effective amount of the active ingredient of the pharmaceutical composition of the present invention means an amount required for preventing or treating a disease.
- the type of disease the severity of the disease, the type and amount of the active ingredient and other ingredients contained in the composition, the type of formulation and the patient's age, weight, general health condition, sex and diet, administration time, administration route and composition It can be controlled by various factors including secretion rate, duration of treatment, and drugs used concurrently.
- the present invention provides a method for isolating stem cells without the use of any exogenous tissue-degrading enzyme and without tissue dissociation during the process of isolating endogenous stem cells from solid tissues. Since no exogenous tissue-degrading enzyme is used, the function and structure of the tissue after isolating the stem cells can be preserved, thus providing a method that can be used as a tissue source capable of repeatedly isolating stem cells from the tissue.
- Tissue endogenous stem cells are known to account for a very small percentage of cells constituting tissues and are usually less than 0.01%. After tissue damage, the number of somatic cells decreases, and stem cells for replacing or regenerating these cells are activated, and the frequency of stem cells increases compared to before damage. After damage, stem cells in the tissue reproduce themselves through cell division and produce daughter progenitor cells, and daughter stem cells migrate to the damaged area.
- This patent provides a method for inducing self-renewal and cell division of stem cells in tissue slices by activating the tissue homeostasis mechanism in vivo through in vitro culture, and mobilizing the self-replicating and dividing stem cells in vitro to damaged sites.
- the present invention maximizes the matrix-cellular integrin interaction through three-dimensional support of the wound repair matrix mimicking hydrogel around the tissue slice to activate stem cells in the tissue, cell division, growth and migration to the wound repair matrix mimic hydrogel and provides a method for isolating stem cells that have migrated into the hydrogel.
- tissue endogenous stem cells are activated, and the activated stem cells have been reported to have increased expression of uPAR or nestin.
- Expression of uPAR and nestin has been found to play an important role in the growth and migration of stem cells, and uPAR+ and nestin+ cells are known to play a pivotal role in tissue regeneration. Since the expression of uPAR and nestin is increased in reparative stem cells, uPAR and nestin can be applied as major target markers for stem cell isolation.
- the present invention provides a method for selectively separating and harvesting uPAR+ stem cells by inducing cell division, growth, and migration of tissue-intrinsic uPAR+ and nestin+ stem cells as a result of matrix-cellular integrin pathway activation through in vitro culture.
- the present invention provides a common method for isolating tissue-intrinsic uPAR+ and nestin+ stem cells from representative solid tissues such as fat, bone marrow, myocardium, nerve, skeletal muscle, and synovial membrane.
- Tissue-intrinsic uPAR+ and nestin+ stem cells can be used as regenerative medicine treatments because they have self-renewal, high in vitro growth, multipotential characteristics, and high tissue regeneration ability.
- the wound repair-imitating hydrogel is prepared by mixing fibrinogen, collagen, gelatin or these polymers.
- Plasma-derived fibrinogen is dissolved in phosphate-buffered saline (PBS) containing 10 to 50 mM CaCl 2 at a concentration of 2.5 to 10 mg/ml to prepare a fibrinogen solution.
- Thrombin is dissolved in PBS at a concentration of 1 to 10 units/ml to prepare a thrombin solution.
- Dermal-derived collagen (Matrix BioScience, Germany) or gelatin (befMatrix Collagen, Nitta Gelatin, Japan) is dissolved in 0.1% (wt./vol.) acetic acid, and a collagen solution having a concentration of 1.0 to 20.0 mg/ml is used.
- 10X buffer solution (Reconstitution Buffer) for preparing a neutral gelatin or collagen solution is prepared with 50 mM NaHCO 3 , 40 mM HEPES, 0.01 N NaOH and mixed with collagen or gelatin solution in a 9:1 volume to obtain a neutral collagen or gelatin solution. manufacture
- the wound repair matrix mimicking hydrogel is prepared by preparing a fibrin hydrogel with a 0.25 to 2.5% fibrinogen solution and a 0.5 to 5 I.U./mL thrombin solution, and a 0.1 to 0.5% concentration range of collagen or gelatin solution. are mixed during production of fibrin hydrogel to prepare fibrin/collagen or fibrin/gelatin mixed hydrogel.
- the organs used for culture are adipose tissue (AT), bone marrow (BM), myocardium (Myocar), peripheral nerve (PN), muscle (skeletal muscle (SM)), synovium (Syn) was used. Approval was obtained from the Institutional Ethics Review Committee for research using brain-dead tissues, and tissues donated from brain-dead individuals were used. Hematoma and fibrous tissue attached to the tissue are removed with scissors, and then the donated tissue is cut into 0.2 to 2 mm 3 pieces using a surgical scalpel. Thereafter, the tissue section is suspended in PBS, centrifuged at 1,000 rpm, and the washing process of removing the supernatant is repeated three times.
- the tissue sections are suspended in a culture medium and cultured by two organ culture methods.
- the first method was defined as a monolayer (2D) organ culture method in which tissue fragments suspended in a culture solution were seeded in a culture container and cultured on the surface of the culture container.
- the second method is defined as a 3D organ culture method in which tissue sections are embedded in fibrin, fibrin/collagen or fibrin/gelatin wound repair matrix-mimicking hydrogel and then cultured in a 3-dimension (3D) environment.
- tissue sections were mixed with 0.25-2.5% fibrinogen solution, mixed with the same amount of 0.5-5 unit/mL thrombin solution in a 1:1 volume, and then polymerized at 37°C for 1 hour. After roughening, the tissue sections were embedded into the fibrin hydrogel.
- Fat, bone marrow, heart, and muscle were embedded in tissue sections in a fibrin hydrogel mimicking wound repair matrix with a final 0.25–1.25% fibrinogen solution and 0.25–2.5 unit/mL thrombin solution.
- Nerve and synovial tissue slices were embedded in a wound repair matrix-mimicking fibrin/collagen or gelatin hydrogel consisting of 0.25–2.5% fibrinogen, 0.1–0.5% collagen or gelatin neutral solution, and 0.25–2.5 unit/mL thrombin solution.
- tissue sections mixed with the wound repair matrix mimicking hydrogel solution were transferred to a 100-mm to 150-mm culture container and then placed in a 37° C. incubator for 1 hour to convert to a gel after polymerization.
- Long-term culture medium is 45% v/v DMEM, 45% v/v Ham's F12, 10% fetal bovine serum (FBS, Invitrogen), 20 ng/ml EGF, 2 ng/ml bFGF, 10 ng/ml IGF , 10 ⁇ g/ml gentamicin (Invitrogen).
- the culture solution was added in an amount corresponding to twice the gel capacity, and after the addition of the culture solution, the culture vessel was placed on an orbital shaker and cultured for 14 days while stirring at a speed of 30 rpm. The culture medium was replaced twice a week.
- tranexamic acid or aminomethyl benzoic acid a PAI
- a PAI a PAI
- tranexamic acid or aminomethyl benzoic acid a PAI
- a PAI a PAI
- tranexamic acid or aminomethyl benzoic acid at a concentration of 100 to 250 ⁇ g/mL was added to the culture medium to suppress wound repair matrix mimic hydrogel degradation.
- tranexamic acid or aminomethyl benzoic acid at a concentration of 250 ⁇ 500 ⁇ g/mL was added to the culture medium and cultured.
- the constituent cells in the tissue slice are activated, and the activated cells proliferate after cell division to replace or regenerate damaged or lost cells.
- the integrin cell signal transduction pathway is one of the main mechanisms that induce tissue regeneration, and the integrin cell signal transduction is activated according to the binding of cell ligands, extracellular matrix and receptors.
- tissue slices in a culture vessel after direct seeding of tissue slices in a culture vessel, monolayer culture (2-dimension, 2D) cultured on the surface of the culture vessel and inside of tissue slices cultured in a 3D (3-dimension, 3D) environment after incorporation into a hydrogel
- pFAK, uPAR, and nestin proteins which are target factors activated as a result of integrin cell signals, were analyzed in constitutive cells.
- uPAR a sub-target factor of the integrin signaling pathway
- 3D physical stimulation of the wound repair matrix-mimicking hydrogel can provide a way to significantly increase cell division and growth by activating the signaling pathways of the constituent cells in the organ.
- pFAK, uPAR, and nestin were expressed in cells in the interstitial space between mature somatic cells, and pFAK, uPAR, and nestin were expressed in pericytes around capillaries rather than capillary vascular endothelial cells.
- Ki-67 a cell division marker, was not expressed in mature somatic cells and was expressed in less than 1% before culture. However, after 3D organ culture in vitro, the expression rate of Ki-67 increased in proportion to the culture period, and after 2 weeks of organ culture, the expression rate of Ki-67 in the myocardium was 45.7%. Through this, it was confirmed that division and growth of cells in the myocardium could be induced, and Ki-67 was also mainly expressed in pericytes (FIG. 4).
- cell division and growth can be induced in the myocardium through the 3D wound repair matrix mimicking hydrogel, and division and growth of pFAK+, uPAR+ and nestin+ pericytes can be induced through long-term culture. confirmed that
- Example 5> In tissue through 3D organ culture uPAR + and nestin + cellular wound healing temperament Induction of migration and growth into mimetic hydrogels
- Anti-uPAR MAB807, R&D Systems, USA
- -nestin MAB5326, Millipore, USA
- -BrdU 347580, BD Biosciences, USA
- HRP-conjugated secondary antibody ImmPRESS One-Step Polymer Systems, Vector Laboratories, USA
- hematoxylin H-3401-500 , Vector Laboratories
- the wound repair matrix mimicking hydrogel serves as an extracellular matrix that can support cell migration and growth, and this can be achieved through the provision of cell adhesion factors such as fibronectin, collagen, and fibrin, which are essential for cell migration.
- 3D wound repair matrix hydrogel activates the integrin-pFAK cell signal signal transmission pathway through receptor-ligand binding to induce cell division and growth of uPAR+ and nestin+ cells in the organ, and mimic uPAR+ and nestin+ cells as the wound repair matrix Mobilization, migration and growth can be induced with hydrogels.
- the cells migrated from the myocardium and grown in the hydrogel had uPAR and nestin expression rates of 88.5% and 95.4%, respectively, and showed the same uPAR+ and nestin+ characteristics as cells that were divided and grown after organ culture in the tissue. More than 89.4% of the cells that migrated into the hydrogel were BrdU-positive, which means that the cells synthesized DNA by uptake of BrdU added during organ culture, so most of the cells in the hydrogel were Prove that the cells in the tissue are cells that have migrated after division and growth. BrdU+ cells were not detected in the myocardium before organ culture, and uPAR+ and nestin+ cells were less than 2%.
- tissue-intrinsic cells were cells that had undergone cell division, growth, and migration to the hydrogel, and no significant difference was observed depending on the tissue (FIG. 6).
- the culture medium was removed. After adding DMEM, washing was performed while stirring at 30 rpm for 30 minutes, and the washing solution was removed. This washing process was repeated 3 times. After washing, the cells that migrated and grew in the hydrogel were separated and recovered in the following two ways.
- the hydrogel was degraded for 2 hours after being added to the culture medium, and the cells and tissue fragments freed from the disintegrated hydrogel were transferred to a tube and then 10 at 3,000 rpm. After centrifugation for 10 minutes, the supernatant was removed, and the collected cell and tissue section pellets were suspended in the culture medium.
- Cells can be separated and collected from the hydrogel by the PAI withdrawal method. After 14 days of long-term culture, the culture medium was removed and washed three times using DMEM to remove the remaining PAI in the culture medium and hydrogel. After adding fresh culture medium, the culture was incubated for 1 hour while stirring at a speed of 30 rpm, and PAI in the culture medium was not added. Cells separated from the hydrogel were collected using a transfer pipette, transferred to tubes, centrifuged at 3,000 rpm for 10 minutes, and the supernatant was removed. The collected cells and tissue fragment pellet were suspended in a culture medium.
- the cells separated and collected from the hydrogel were suspended in a culture medium, and the total number of cells was calculated using a hemocytometer, and the uPAR expression rate of the collected cells was analyzed using flow cytometry.
- uPAR+/nestin+ cells grown after cell division in the tissue induce migration and growth into the hydrogel, and the cells that migrate and grow within the hydrogel become hydrogels according to the plasmin activity of uPAR+/nestin+ cells themselves without exogenous protease. It is intended to provide a method for selectively separating and collecting uPAR+/nestin+ cells by dissolving the gel through this embodiment.
- uPAR mRNA expression and plasmin activity were evaluated in tissue sections before and after organ culture. Even before in vitro culture, uPAR mRNA expression and plasmin activity were different according to organs, and uPAR mRNA expression and plasmin activity were higher in myocardium, nerve, and skeletal muscle than in other tissues (FIG. 7). In all tissue sections evaluated after organ culture, uPAR mRNA expression and plasmin activity significantly increased compared to before culture. In particular, mRNA expression and plasmin activity were the highest in myocardium, nerve and skeletal muscle. Since Plasmin activity is proportional to uPAR expression, it is possible to induce an increase in uPAR expression in tissues through organ culture, and provides a method to increase plasmin activity in tissues through increased uPAR after organ culture. do.
- Plasminogen Activator Inhibitor is added in the culture medium during 3D organ culture, and the added PAI can inhibit hydrogel degradation by controlling excessive plasmin and protease activity in organs and cells.
- PAI Plasminogen Activator Inhibitor
- cell division and growth in tissue are induced to move and grow into the hydrogel, and then the PAI is removed from the culture medium and hydrogel through washing and washing. and protease activity alone can induce hydrogel disassembly, and as a result, cells that have migrated and grown in the hydrogel are released, and the freed cells can be separated and collected.
- PAI withdrawal is performed by removing the PAI-containing culture medium, washing it with DMEM three times to remove the PAI remaining in the hydrogel and organs through the washing process, and adding twice the amount of the hydrogel to the culture medium without PAI. did After 30 minutes of incubation, the hydrogel began to degrade as a result of PAI withdrawal. As the hydrogel disintegrated, the cells that migrated within the hydrogel were released from the hydrogel and aggregated between cells, and after 2 hours of culture, tissue sections and cells that migrated grew. The surrounding hydrogel is completely degraded, resulting in dissociation of the cells within the hydrogel (FIG. 8).
- the wound repair matrix mimicking hydrogel is lost due to cell-specific plasmin and protease activity, and the cells in the hydrogel are released into the culture medium.
- the cells released in the culture medium have their cytoplasm contracted and aggregated It can be separated and recovered in the form.
- Hydrogel degradation can be inhibited through the addition of PAI during long-term culture, and the cells in the hydrogel show a spindle-shaped shape as a result of cytoplasmic expansion.
- degradation begins from the hydrogel around the cells through PAI withdrawal in the culture medium, and as a result, the cytoplasm of the cells shrinks, and as a result of cell-cell junctions, the cells form aggregates, and the aggregated cells are released into the culture medium. (FIG. 9).
- Cells that have migrated and grown in the hydrogel can be isolated and harvested after PAI withdrawal or urokinase treatment.
- the present invention compared and evaluated the usefulness of a method for isolating migratory and grown cells in a hydrogel with PAI withdrawal without urokinase treatment.
- the uPAR expression rate of cells harvested after PAI withdrawal was significantly higher than that of cells harvested after urokinase treatment (FIG. 11B).
- the yield of selectively isolating uPAR+ cells from tissues with high uPAR expression and plasmin activity was high. This has high hydrogel degradation activity in uPAR+ cells, and as a result, it can be verified that the method is highly efficient in selectively separating uPAR+ cells by removing PAI and washing.
- the culture medium was removed. After adding DMEM, washing was performed while stirring at 30 rpm for 30 minutes, and the washing solution was removed. The washing process was repeated three times to remove remaining PAI in the culture medium and hydrogel. After adding fresh culture medium, the culture was incubated for 2 hours while stirring at a speed of 30 rpm, and PAI in the culture medium was not added. Cells and tissue fragments separated from the hydrogel were collected using a transfer pipette, transferred to tubes, centrifuged at 3,000 rpm for 10 minutes, and the supernatant was removed.
- tissue fragments precipitate faster than cells as a result of their high specific gravity
- the cell and tissue fragment pellets are dispersed in DMEM, left for 30 seconds to induce sedimentation of the tissue fragments, and only the supernatant is transferred to a new tube. This process is repeated three times. The harvested cells and tissue sections were separated.
- Tissue sections separated from the hydrogel by the PAI withdrawal method were re-embedded into the hydrogel, followed by 3D organ culture by the method described in Example 2, and 2 weeks later by the method described in Example 7.
- Cells and tissue sections that had migrated within the gel were separated and harvested.
- the tissue fragments recovered after PAI withdrawal were subjected to three more consecutive 3D organ cultures to induce migration and growth of cells in the tissue repeatedly, and the cells in the hydrogel were separated and recovered, and the total number of cells separated and recovered was measured using a hemocytometer.
- tissue sections with preserved structures are recovered, and the recovered tissue sections are subjected to repeated organ culture to isolate cells that have migrated into the hydrogel after organ culture and grown. and provide a method for collection.
- Treatment with an exogenous protease such as urokinase can degrade the hydrogel and the infiltrated tissue slice, resulting in the loss of the structural and functional microenvironment of the tissue slice.
- the PAI withdrawal method is a method capable of preserving the structural and functional microenvironment of tissue slices infiltrated together with cells that have migrated and grown in the hydrogel after 3D organ culture. It can be confirmed that this is a method for isolating tissue-intrinsic cells with high efficiency and stability.
- 3D organ culture After embedding fat, bone marrow, myocardium, nerve, skeletal muscle, and synovial tissue sections in fibrin or fibrin/collagen hydrogel, 3D organ culture was performed. The long-term culture solution was added twice as much as the hydrogel capacity, and the culture vessel was placed on an orbital shaker and cultured for 14 days while stirring at a speed of 30 rpm. To inhibit hydrogel degradation, tranexamic acid, a PAI, was added to the culture medium every day.
- the culture medium was removed. After adding DMEM, the mixture was washed for 30 minutes while stirring at a speed of 30 rpm, and this washing process was repeated three times. Cells that migrated and grew in the hydrogel after washing were collected after separating the cells by the PAI withdrawal or urokinase method presented in Example 6. After 14 days of long-term culture, the culture medium was removed and washed three times using DMEM to remove the remaining PAI in the culture medium and hydrogel. After adding fresh culture medium, the culture was incubated for 1 hour while stirring at a speed of 30 rpm, and PAI in the culture medium was not added. Cells separated from the hydrogel were collected using a transfer pipette, transferred to tubes, centrifuged at 3,000 rpm for 10 minutes, and the supernatant was removed. The collected cells and tissue fragment pellet were suspended in a culture medium.
- Urokinase treatment is performed after washing three times, adding 1,000 unit/mL urokinase to the culture medium, dissolving the hydrogel for 2 hours, collecting cells and tissue fragments freed from the disintegrated hydrogel, transferring them to a tube at 3,000 rpm for 10 minutes After centrifugation, the supernatant was removed, and the collected cell and tissue section pellets were suspended in the culture medium.
- the cells separated and collected from the hydrogel were seeded at 5,000 cells per cm2 in a polystyrene culture container, and then the culture medium was added.
- the adhesion and growth characteristics of the cells separated and collected from the hydrogel in a monolayer culture environment were evaluated using a microscope.
- FIG. 13A After PAI withdrawal, it was confirmed that cell aggregates were formed after being released from the hydrogel (FIG. 13A), and the collected cells were suspended in a culture medium and composed of small circular aggregates (FIG. 13B), and seeded in a PS culture container to form a monolayer. cultured in the environment. Cells harvested in an aggregated state adhered to the culture vessel 30 minutes after seeding (FIG. 13C), the cytoplasm of the cells seeded 1 hour after seeding expanded (FIG. 13D), and the cells were stably attached after 2 hours of culture. and growth of cells around the cell aggregates was confirmed (FIG. 13E).
- tissue sections such as fat, bone marrow, myocardium, nerve, skeletal muscle, and synovial membrane
- cells could be stably separated and collected through PAI withdrawal. It was confirmed that all the cells collected within 30 minutes adhered to the culture vessel and stably expanded the cytoplasm, and there was no significant difference according to the tissue (FIG. 14).
- the culture medium was removed. After adding DMEM, the mixture was washed for 30 minutes while stirring at a speed of 30 rpm, and this washing process was repeated three times. After washing, the cells that migrated and grew in the hydrogel were collected after separating the cells by the PAI withdrawal method. After 14 days of long-term culture, the culture medium was removed and washed three times using DMEM to remove the remaining PAI in the culture medium and hydrogel. After adding fresh culture medium, the culture was incubated for 1 hour while stirring at a speed of 30 rpm, and PAI in the culture medium was not added. Cells separated from the hydrogel were collected using a transfer pipette, transferred to tubes, centrifuged at 3,000 rpm for 10 minutes, and the supernatant was removed. The collected cells and tissue fragment pellet were suspended in a culture medium.
- MSC Mesenchymal stem cell
- Cells grown by migration from the hydrogel as a result of urokinase treatment or PAI withdrawal can be separated and collected. Regardless of the cell collection method, the cells grown in the hydrogel from all cultured tissues showed the same immunorepresentation characteristics as mesenchymal stem cells, with CD29, CD73, CD105, and CD140b expression rates of 90% or more (FIG. 16A). There was no difference in the expression rate of mesenchymal stem cell markers in the cells separated and collected from the hydrogel according to the separation method.
- Hematopoietic cells and vascular endothelial cells present in tissues may be mixed during the process of separating cells from tissues, and the degree of mixing of these cells may be confirmed by identifying CD31+, CD34+, and CD45+ cells.
- the expression rate of CD31, CD34, and CD45 was less than 1%, but the cells separated and collected after treatment with Urokinase were 2.8 ⁇ 7.0%, confirming a high mixing of hematopoietic cells and vascular endothelial cells. could (FIG. 17).
- the method selectively separates and collects uPAR+ and nestin+ cells that have migrated from the tissue into the hydrogel through PAI withdrawal, and at the same time, mixing of hematopoietic cells and vascular endothelial cells during the separation process can be minimized. .
- CFU colony forming assay
- the frequency of CFU formation was different depending on the tissue type, in all tissue sections, the cells separated and collected from the hydrogel through PAI withdrawal were significantly higher than those collected after treatment with urokinase (FIG. 18). In particular, cells derived from cardiac muscle, nerve and skeletal muscle showed high colony formation ability compared to cells derived from other tissues. In the case of cells isolated after urokinase treatment, the CFU frequency was 3.1 ⁇ 8.4%, but cells isolated by the PAI withdrawal method had a high CFU frequency of 8.8 ⁇ 37.9%.
- Self-renewal ability is one of the main characteristics of stem cells, and 3D organ culture can activate stem cells in tissues to induce migration and growth into hydrogels. Stem cells with high self-replication titer can be selectively separated and collected, which is a result proving that uPAR+/nestin+ cells with high plasmin activity are stem cells with high titer (FIG. 18).
- the cells separated and collected from the hydrogel were transferred to tubes, centrifuged at 3,000 rpm for 10 minutes, and the supernatant was removed. The cell precipitate was resuspended in the culture medium and then adjusted to a density of 1.0E+06 cells per mL.
- cell doubling time population doubling time, PDT
- cell doubling level population doubling level, PDL
- 3,000 cells per cm 2 were seeded in a T75 flask, cultured for 7 days, and cells were collected after treatment with trypsin/EDTA, and the total number of cells was calculated using a hemocytometer.
- PDT and PDL were calculated and compared through the number of disseminated cells, the total number of harvested cells, and the culture period.
- Ki-67 a cell cycle marker
- In vitro cell growth ability was compared and analyzed by analyzing the anti-Ki67 expression rate by flow cytometry.
- Ki-67 expression was analyzed by flow cytometry to verify the high growth ability of the cells separated and collected from the hydrogel after PAI withdrawal treatment. Since the Ki-67 marker refers to cells in the cell cycle, the higher the Ki-67 expression rate, the higher the cell growth ability. Cells obtained through PAI withdrawal showed a high Ki-67 expression rate of 58.5 to 75.4%, which was significantly higher than 33.6 to 48.7% in cells obtained after urokinase treatment (FIG. 20).
- PAI withdrawal is a method for selectively isolating cells with high in vitro growth potential, which supports that uPAR+/nestin+ cells with high plasmin activity are cells with high growth potential.
- the cells separated and collected from the hydrogel were transferred to tubes, centrifuged at 3,000 rpm for 10 minutes, and the supernatant was removed. The cell precipitate was resuspended in the culture medium and then adjusted to a density of 1.0E+06 cells per mL. The ability of the cells in the hydrogel to differentiate into adipocytes and osteoblasts was evaluated. After seeding 2.0E+05 cells in a 24-well culture dish, 10% CS, 0.5 mM 3-isobutyl-1-methylxanthine (Sigma), 80 ⁇ M indomethacin (Sigma), 1 ⁇ M DEX, 5 ⁇ g/ml in 90% DMEM After adding mL insulin-added differentiation medium, it was cultured for 14 days.
- the degree of differentiation of stem cells into adipocytes was examined by staining with 0.5% Oil Red O (Sigma) solution, which is an indicator of fat accumulation in the cytoplasm, for 1 hour at room temperature 2 weeks after differentiation induction, and the triglyceride content in the cytoplasm was measured using the Triglyceride-Glo kit (Promega). evaluated using In order to evaluate the ability to differentiate into osteoblasts, 2.0E+05 cells were seeded in a 24-well culture container, and then ⁇ containing 1 ⁇ M DEX, 50 ⁇ M Ascorbic Acid, 10 mM ⁇ -glycerol phosphate, and 10% calf serum. After adding -MEM, differentiation was induced by culturing for 2 weeks. Whether or not to differentiate into osteoblasts was stained after 2 weeks of induction of differentiation by adding Alizarin Red (Sigma), and the degree of mineral deposition was measured by optical density by measuring absorbance at 520 nm.
- Oil Red O Sigma
- FIG. 21 shows that cells separated and collected from the bone marrow were differentiated into osteoblasts (left) and adipocytes (right), and then calcium phosphate crytal accumulation and deposition were confirmed by alizarin red staining, and differentiation into adipocytes was induced.
- the accumulation of lipids in the cytoplasm of cells can be confirmed by oil red O staining. It was confirmed that all cells derived from all tissue sections had the ability to differentiate into osteoblasts and adipocytes.
- osteoblast and adipocyte differentiation abilities were compared and evaluated through the OD values measured after dissolving deposited or accumulated mineral cryostal and fat vacuole.
- OD values measured after dissolving deposited or accumulated mineral cryostal and fat vacuole.
- the ability of cells separated and collected from the hydrogel by PAI withdrawal to differentiate into osteoblasts and adipocytes was significantly higher than that of cells isolated and collected after treatment with urokinase (FIG. 22).
- Differentiation into osteoblasts showed high ability in bone marrow, cardiac muscle, and skeletal muscle-derived cells, and differentiation into adipocytes showed high ability in fat, skeletal muscle, and synovial membrane.
- the cells separated and collected from the hydrogel were transferred to tubes, centrifuged at 3,000 rpm for 10 minutes, and the supernatant was removed.
- the cell precipitate was resuspended in the culture medium and then adjusted to a density of 1.0E+06 cells per mL. After seeding 5.0E+06 cells in a T175 flask and culturing for 3 days, 1 mL of TRIzol was added, cell lysate was collected, and stored frozen at -20°C until total RNA was isolated.
- Total RNA was extracted and purified using the PureLink RNA kit (Thermo Fisher), and cDNA was synthesized using reverse transcriptase.
- bFGF Basic FGF
- HGF HGF
- IGF IGF
- SDF-1 mRNA expression which plays a major role in tissue protection and regeneration
- CB-MSC cord blodd-derived mesenchymal stem cells
- the target mRNA gene was amplified through real-time gene amplification using a target mRNA specific primer and SYBR Green Real-Time PCR kit, and the mRNA expression rate compared to cord blood-derived mesenchymal stem cells (CB-MSC) was evaluated by the 2- ⁇ Ct method.
- tissue regeneration inducing ability of the collected cells was compared and analyzed through the expression of related mRNAs.
- tissue regeneration inducing ability of the collected cells was compared and analyzed through the expression of related mRNAs.
- gene expression inducing tissue regeneration was different. Expression of these genes was high in cardiomyocyte, nerve and skeletal muscle-derived cells. HGF and SDF-1 mRNA were high in cardiomyocyte-derived cells, but IGF in nerve-derived cells. mRNA expression was high [Fig. 23].
- the expression of all tissue regeneration genes was significantly higher in the cells isolated and collected by PAI withdrawal compared to the cells isolated and collected after urokinase treatment.
- uPAR+ cells have Ki-67 expression of 40.8 ⁇ 82.4%, which is significantly higher than that of uPAR- cells, Ki-67 expression of 28.1 ⁇ 45.7%. (Fig. 25, right). Cardiac, nerve, and skeletal muscle-derived uPAR+ cells showed higher CFU formation ability and Ki-67 expression compared to other tissues.
- Anti-inflammatory ability was evaluated using conditioned media containing factors secreted from cells.
- conditioned media containing factors secreted from cells.
- UK+uPAR+, UK+uPAR- and PAI withdrawal cells were cultured for 1 week after adding DMEM/F12 serum-free medium seeded with 40,000 cells per cm 2 in a T175 flask.
- RAW 264.7 cells were suspended in 90% RPMI 1640/10% calf serum, and 100,000 cells per cm 2 were seeded in a 12-multiwell plate and cultured for 1 day.
- RAW 264.7 cells were sensitized by adding 100 ⁇ g/mL LPS to the culture.
- the anti-inflammatory ability was evaluated by adding the conditioned medium to the culture medium at a ratio of 1:10.
- Anti-inflammatory evaluation indicators were compared and evaluated by measuring the levels of TNF ⁇ and IL-1 ⁇ secreted from RAW 264.7 cells by ELISA method.
- RAW 264.7 cells showed a 5-fold increase in TNF ⁇ and IL-1 ⁇ secretion levels after LPS stimulation. Substances secreted from tissue endogenous stem cells separated and collected from the hydrogels were confirmed to have the ability to inhibit inflammatory cytokine separation of RAW 264.7 cells by 30 to 70% (FIG. 26).
- the conditioned medium prepared from UK+uPAR+ cells and PAI withdrawal cells showed significantly higher TNF ⁇ and IL-1 ⁇ secretion inhibition ability than UK+uPAR ⁇ cells. Regardless of the tissue of origin, uPAR+ cells showed higher anti-inflammatory effects compared to uPAR- cells.
- vascular endothelial cells human umbilical vein endothelial cells (HUVEC) were used, and human dermal fibroblasts (DF) were used.
- the growth-inducing effect of the conditioned medium on the cells was tested.
- a conditioned medium prepared by the method described in Example 16 was prepared and the efficacy was tested.
- HUVEC cells and DFs were suspended in 99% DMEM/1% calf serum culture medium, and 4,000 cells per cm2 were seeded in a 24-multiwell plate.
- the conditioned medium was added at a ratio of 1:9 to the culture medium and cultured for 3 days, and the number of cells after culture was measured using the PicoGreen dsDNA quantitation kit (Invitrogen).
- the cell growth effect was compared and analyzed by calculating the increase in the number of cells seeded first.
- the conditioned medium prepared from UK+uPAR+ and PAI withdrawal cells was confirmed to have an effect on promoting HUVEC and DF growth, and showed a significantly higher potency than the conditioned medium prepared from UK+uPAR- cells by more than 30%, but the UK+uPAR+ There was no difference in potency between PAI withdrawal cells (FIG. 27).
- the conditioned media obtained from myocardial, nerve, and skeletal muscle-derived stem cells were confirmed to have a high growth inducing effect compared to other tissue-derived stem cells.
- the cytoprotective effect was tested using conditioned media prepared from UK+uPAR- cells, UK+uPAR+ cells, and cells separated and harvested after PAI withdrawal. After suspending HUVECs and DFs in 99% DMEM/1% calf serum culture medium, 5,000 cells per cm 2 were seeded in a 24-multiwell plate. One hour before the induction of H 2 O 2 -mediated cell damage, the conditioned medium was added at a ratio of 1:9 to the culture medium. Cell damage was induced by adding 0.01% H 2 O 2 , and after 6 hours of damage induction, the culture medium was removed and washed twice with PBS. The degree of cell damage was evaluated by annexin V expression rate, and after reacting FITC-conjugated annexin V (BD Biosciences) with the cells, the apoptotic cells were analyzed by flow cytometry.
- the expression rate of annexin V in HUVECs and DFs treated with UK+uPAR+ cell conditioned medium was 28.7 ⁇ 45.1%, which showed a significantly higher cytoprotective effect than 42.1 ⁇ 71.3% in cells treated with UK+uPAR- cell conditioned medium.
- a significant difference from the PAI withdrawal cell-derived conditioned medium could not be confirmed.
- the present invention is achieved through long-term culture supported by artificial wound repair matrix (engineered provisional matrix).
- Tissue slices are embedded in an artificial provisional matrix and the integrin-FAK cell signaling pathway is activated through the provisional matrix to induce cell division and growth of tissue endogenous stem cells.
- the stem cells in the tissue move to the provisional matrix and the growth increases in proportion to the activity of uPAR-uPA-plasmin.
- Excessive provisional matrix decomposition can be controlled through the addition of PAI to control the result of inhibition and cessation of stem cell migration due to decomposition and loss of provisional matrix due to excessive uPAR-uPA-plasmin activity.
- the present invention provides a technology for isolating and culturing uPAR+ stem cells without the use of any tissue degradation protein and stem cell purification process using markers by using the migration and degradation characteristics of provisional matrix according to uPAR expression.
- the present invention can be applied to the isolation and culture of uPAR+ stem cells present in solid tissues such as bone marrow, fat, skeletal muscle, heart, peripheral nerves, spinal cord, brain, lung, liver, joint membrane, umbilical cord, placenta, and periodontium.
- solid tissues such as bone marrow, fat, skeletal muscle, heart, peripheral nerves, spinal cord, brain, lung, liver, joint membrane, umbilical cord, placenta, and periodontium.
- the present invention provides a method for isolating and culturing stem cells through repeated long-term culture by isolating stem cells without any tissue degradation enzyme treatment so that the tissue fragments used for organ culture can preserve their structure intact.
- the present invention shows the characteristic of positively expressing common stem cell markers along with uPAR among uPAR-positive tissue endogenous stem cells.
- mesenchymal stem cell markers CD29, CD44, CD73, CD90, and CD105 are expressed positively, but hematopoietic stem cell or vascular endothelial cell markers are negative.
- uPAR-positive stem cells derived from peripheral nerve, spinal cord, and brain tissue show the characteristics of simultaneously expressing markers such as nestin, p75, Sox10, and Sox2.
- the uPAR-positive stem cells of the present invention show biological characteristics of high secretion of physiologically active factors acting on migration, growth factors, anti-inflammatory factors, stem cell mobilization factors, and tissue regeneration.
- the uPAR-positive stem cells of the present invention have a high multipotential ability to differentiate into tissue-constituting cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (18)
- (1) 창상수복기질 모방 하이드로젤을 제조하는 단계;(2) 분리된 조직 절편을 상기 창상수복기질 모방 하이드로젤 내로 함입시키는 단계; 및(3) 상기 조직 절편이 함입된 창상수복기질 모방 하이드로젤을 플라스미노겐 활성 억제제(plasminogen activator inhibitor; PAI)가 첨가된 배양액에서 3차원 배양하는 단계를 포함하는 조직 내재성 uPAR+ 및 nestin+ 줄기세포의 활성화 방법.
- 제1항에 있어서, 상기 창상수복기질 모방 하이드로젤은 0.25 ~ 2.5% 농도의 피브리노겐 용액 및 0.5 ~ 5 I.U./mL 농도의 트롬빈 용액이 혼합된 피브린 하이드로젤, 상기 피브린 하이드로젤에 0.1 ~ 0.5% 농도의 콜라겐 용액이 혼합된 피브린/콜라겐 혼합 하이드로젤 또는 상기 피브린 하이드로젤에 0.1 ~ 0.5% 농도의 젤라틴 용액이 혼합된 피브린/젤라틴 혼합 하이드로젤인 것을 특징으로 하는 조직 내재성 uPAR+ 및 nestin+ 줄기세포의 활성화 방법.
- 제1항에 있어서, 상기 조직은 지방 조직, 골수 조직, 심근 조직, 말초 신경 조직, 골격근 조직 또는 활액막 조직인 것을 특징으로 하는 조직 내재성 uPAR+ 및 nestin+ 줄기세포의 활성화 방법.
- 제1항에 있어서, 상기 PAI는 트라넥사민산(tranexamic acid) 또는 아미노메틸 벤조익산(aminomethyl benzoic acid)인 것을 특징으로 하는 조직 내재성 uPAR+ 및 nestin+ 줄기세포의 활성화 방법.
- 제1항에 있어서, 상기 방법은 조직 내 세포의 인테그린(integrin)-FAK 세포신호 전달을 활성화시켜, 조직 내재성 uPAR+ 및 nestin+ 줄기세포의 세포분열 및 세포성장을 유도하는 것을 특징으로 하는 조직 내재성 uPAR+ 및 nestin+ 줄기세포의 활성화 방법.
- 제1항에 있어서, 상기 방법은 상기 조직 내재성 uPAR+ 및 nestin+ 줄기세포의 창상수복기질 모방 하이드로젤 내로 세포이동 및 세포성장을 유도하는 것을 특징으로 하는 조직 내재성 uPAR+ 및 nestin+ 줄기세포의 활성화 방법.
- (1) 창상수복기질 모방 하이드로젤을 제조하는 단계;(2) 분리된 조직 절편을 상기 창상수복기질 모방 하이드로젤 내로 함입시키는 단계;(3) 상기 조직 절편이 함입된 창상수복기질 모방 하이드로젤을 PAI가 첨가된 배양액에서 3차원 배양하는 단계;(4) 상기 3차원 배양액을 제거하고 세척하여 PAI를 제거하는 단계;(5) 상기 PAI가 제거된 배양물을 PAI가 함유되지 않은 배양액으로 재배양하여 상기 창상수복기질 모방 하이드로젤을 분해시키는 단계; 및(6) 상기 재배양액 내에 유리된 줄기세포를 분리하는 단계를 포함하는 조직 내재성 uPAR+ 및 nestin+ 줄기세포의 분리배양 방법.
- 제7항에 있어서, 상기 창상수복기질 모방 하이드로젤은 0.25 ~ 2.5% 농도의 피브리노겐 용액 및 0.5 ~ 5 I.U./mL 농도의 트롬빈 용액이 혼합된 피브린 하이드로젤, 상기 피브린 하이드로젤에 0.1 ~ 0.5% 농도의 콜라겐 용액이 혼합된 피브린/콜라겐 혼합 하이드로젤 또는 상기 피브린 하이드로젤에 0.1 ~ 0.5% 농도의 젤라틴 용액이 혼합된 피브린/젤라틴 혼합 하이드로젤인 것을 특징으로 하는 조직 내재성 uPAR+ 및 nestin+ 줄기세포의 분리배양 방법.
- 제7항에 있어서, 상기 조직은 지방 조직, 골수 조직, 심근 조직, 말초 신경 조직, 골격근 조직 또는 활액막 조직인 것을 특징으로 하는 조직 내재성 uPAR+ 및 nestin+ 줄기세포의 분리배양 방법.
- 제7항에 있어서, 상기 PAI는 트라넥사민산(tranexamic acid) 또는 아미노메틸 벤조익산(aminomethyl benzoic acid)인 것을 특징으로 하는 조직 내재성 uPAR+ 및 nestin+ 줄기세포의 분리배양 방법.
- 제7항에 있어서, 상기 (5) 단계는 상기 조직 내 uPAR 발현 증가를 유도하고, 플라스민(plasmin) 활성도 증가를 통해, 상기 창상수복기질 모방 하이드로젤을 분해시키는 것을 특징으로 하는 조직 내재성 uPAR+ 및 nestin+ 줄기세포의 분리배양 방법.
- 제7항에 있어서, 상기 조직 내재성 uPAR+ 및 nestin+ 줄기세포는 자기복제능, 체외 성장능, 분화능 또는 조직재생 유도능이 증진된 것을 특징으로 하는 조직 내재성 uPAR+ 및 nestin+ 줄기세포의 분리배양 방법.
- 제7항에 있어서, 상기 (5) 단계의 재배양액으로부터 회수된 조직 절편은 상기 (2) 단계 내지 (5) 단계를 1 내지 10회 반복하는 과정을 더 포함하는 것을 특징으로 하는 조직 내재성 uPAR+ 및 nestin+ 줄기세포의 분리배양 방법.
- 제7항 내지 제13항 중 어느 한 항의 방법에 따라 분리배양된 조직 내재성 uPAR+ 및 nestin+ 줄기세포 또는 이의 배양액.
- 제14항에 따른 조직 내재성 uPAR+ 및 nestin+ 줄기세포 또는 이의 배양액을 유효성분으로 포함하는 염증 질환 예방 또는 치료용 약학조성물.
- 제14항에 따른 조직 내재성 uPAR+ 및 nestin+ 줄기세포 또는 이의 배양액을 유효성분으로 포함하는 자가면역질환 예방 또는 치료용 약학조성물.
- 제14항에 따른 조직 내재성 uPAR+ 및 nestin+ 줄기세포 또는 이의 배양액을 유효성분으로 포함하는 창상 치료용 약학조성물.
- 제14항에 따른 조직 내재성 uPAR+ 및 nestin+ 줄기세포 또는 이의 배양액을 유효성분으로 포함하는 혈관 재생 촉진용 약학조성물.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280039679.8A CN117413050A (zh) | 2021-06-03 | 2022-06-03 | 分离和培养组织驻留uPAR+/巢蛋白+干细胞的方法及其用途 |
EP22816495.0A EP4349963A1 (en) | 2021-06-03 | 2022-06-03 | Method for isolating and culturing tissue-resident upar+/nestin+ stem cells, and use thereof |
JP2023571790A JP2024518626A (ja) | 2021-06-03 | 2022-06-03 | 組織内在性uPAR+/Nestin+幹細胞の分離培養方法及びその用途 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20210072137 | 2021-06-03 | ||
KR10-2021-0072137 | 2021-06-03 | ||
KR1020220067722A KR102476348B1 (ko) | 2021-06-03 | 2022-06-02 | 조직 내재성 uPAR+/Nestin+ 줄기세포 분리 배양 방법 및 이의 용도 |
KR10-2022-0067722 | 2022-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022255836A1 true WO2022255836A1 (ko) | 2022-12-08 |
Family
ID=84324431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/007910 WO2022255836A1 (ko) | 2021-06-03 | 2022-06-03 | 조직 내재성 uPAR+/Nestin+ 줄기세포 분리 배양 방법 및 이의 용도 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4349963A1 (ko) |
JP (1) | JP2024518626A (ko) |
KR (1) | KR20220166770A (ko) |
WO (1) | WO2022255836A1 (ko) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130124075A (ko) * | 2012-05-04 | 2013-11-13 | 인제대학교 산학협력단 | 심장전구세포의 배양방법 및 그 용도 |
KR20130124077A (ko) * | 2012-05-04 | 2013-11-13 | 인제대학교 산학협력단 | 골격근줄기세포의 배양방법 및 그 용도 |
KR20180071665A (ko) * | 2016-12-20 | 2018-06-28 | 인제대학교 산학협력단 | 심장줄기세포의 다층세포시트 및 이의 제조방법 |
KR20180071666A (ko) * | 2016-12-20 | 2018-06-28 | 인제대학교 산학협력단 | 신경능선줄기세포의 다층세포시트 및 이의 제조방법 |
-
2022
- 2022-06-03 WO PCT/KR2022/007910 patent/WO2022255836A1/ko active Application Filing
- 2022-06-03 JP JP2023571790A patent/JP2024518626A/ja active Pending
- 2022-06-03 EP EP22816495.0A patent/EP4349963A1/en active Pending
- 2022-12-05 KR KR1020220167670A patent/KR20220166770A/ko active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130124075A (ko) * | 2012-05-04 | 2013-11-13 | 인제대학교 산학협력단 | 심장전구세포의 배양방법 및 그 용도 |
KR20130124077A (ko) * | 2012-05-04 | 2013-11-13 | 인제대학교 산학협력단 | 골격근줄기세포의 배양방법 및 그 용도 |
KR20180071665A (ko) * | 2016-12-20 | 2018-06-28 | 인제대학교 산학협력단 | 심장줄기세포의 다층세포시트 및 이의 제조방법 |
KR20180071666A (ko) * | 2016-12-20 | 2018-06-28 | 인제대학교 산학협력단 | 신경능선줄기세포의 다층세포시트 및 이의 제조방법 |
Non-Patent Citations (1)
Title |
---|
LOSKUTOFF D J, QUIGLEY J P: "PAI-1, fibrosis, and the elusive provisional fibrin matrix", THE JOURNAL OF CLINICAL INVESTIGATION, B M J GROUP, GB, vol. 106, no. 12, 1 December 2000 (2000-12-01), GB , pages 1441 - 1443, XP002978471, ISSN: 0021-9738, DOI: 10.1172/JCI11765 * |
Also Published As
Publication number | Publication date |
---|---|
JP2024518626A (ja) | 2024-05-01 |
EP4349963A1 (en) | 2024-04-10 |
KR20220166770A (ko) | 2022-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Majumdar et al. | Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages | |
US20130295060A1 (en) | Method for culturing cardiac progenitor cells and use of cardiac progenitor cells | |
AU2015243575B2 (en) | Improved stem cell composition | |
WO2018117569A1 (ko) | 심장줄기세포의 다층세포시트 및 이의 제조방법 | |
WO2018021879A1 (ko) | 암세포의 증식을 억제하는 중간엽 줄기세포의 제조방법 | |
WO2018117573A1 (ko) | 신경능선줄기세포의 다층세포시트 및 이의 제조방법 | |
WO2019004792A9 (ko) | 인간 유래 심장 줄기세포 미세구의 제조 방법 및 용도 | |
WO2020004893A1 (ko) | 인간 유도 만능 줄기세포로부터 연골세포의 펠렛을 제조하는 방법 및 이의 용도 | |
WO2013165120A1 (ko) | 신경능선줄기세포의 배양방법 및 그 용도 | |
KR101956442B1 (ko) | 줄기세포의 효능 개선을 위한 조성물 및 방법 | |
WO2012008733A2 (ko) | 1기 태반조직 유래 줄기세포 및 이를 함유하는 세포치료제 | |
Ma et al. | Immune tolerance of mesenchymal stem cells and induction of skin allograft tolerance | |
WO2011102680A2 (ko) | Pi3k/akt/gsk3 경로를 통해 성체줄기세포의 증식, 다분화능 및 재프로그래밍을 촉진하는 cd49f | |
Cancedda et al. | Transit Amplifying Cells (TACs): a still not fully understood cell population | |
WO2022255836A1 (ko) | 조직 내재성 uPAR+/Nestin+ 줄기세포 분리 배양 방법 및 이의 용도 | |
WO2022004938A1 (ko) | 유사 중간엽 줄기세포의 제조방법 | |
WO2019190246A1 (ko) | 인간 제대로부터 줄기세포를 분리하는 방법 | |
WO2020067774A1 (ko) | 활액막 유래 중간엽 줄기세포 및 그의 용도 | |
WO2018162740A2 (en) | Cell culture supplements | |
WO2016117960A1 (ko) | 면역질환 치료 효능을 갖는 grim19이 과발현된 중간엽줄기세포 및 이의 용도 | |
WO2015072708A1 (ko) | 성체 섬유모세포를 형질전환(이형분화)시켜 혈관내피세포를 제조하는 방법 및 이의 용도 | |
KR102476348B1 (ko) | 조직 내재성 uPAR+/Nestin+ 줄기세포 분리 배양 방법 및 이의 용도 | |
WO2021096218A1 (ko) | 혈관 내피세포 순수 분리 방법, 혈관 내피세포 특성 유지 배지 및 이를 포함하는 배양 방법 | |
WO2021187911A1 (ko) | 제대혈 혈장 유래의 엑소좀 또는 이의 모방체 및 이의 약학적 용도 | |
WO2013162330A1 (ko) | 키메라 중간엽 줄기세포군, 그의 제조방법 및 편도줄기세포를 이용하여 부갑상선 호르몬을 생산하는 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22816495 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023571790 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280039679.8 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022816495 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022816495 Country of ref document: EP Effective date: 20240103 |